The H,K-ATPase that is found in the stomach is the key target for the treatment of disorders connected to acid. PPIs are weak bases that are made up of two different moieties: a substituted pyridine that has a primary pKa of about 4.0 and a benzimidazole that has a secondary pKa of about 1.0. This allows for selective accumulation in the secretory canaliculus of the parietal cell. Proton pump inhibitors (PPIs) are used to treat conditions such as peptic ulcer disease. PPIs are acid-activated prodrugs that, when exposed to an acidic environment, transform to sulfenic acids or sulfenamides, which then react covalently with one or more cysteines that are accessible from the luminal surface of the ATPase. Their inhibitory effects continue for a far longer period of time than their plasma half-life does because of the covalent binding. However, their efficacy in acid suppression is diminished, particularly throughout the night, due to the short half-life of the medication in the circulation as well as the requirement for acid activation. PPIs that have a longer half-life have the potential to provide better acid control. Every proton pump inhibitor (PPI) is capable of producing beneficial outcomes in patients with reflux esophagitis and peptic ulcer disease. When used in conjunction with antibiotics, PPIs are able to completely eradicate Helicobacter pylori.